Details for Patent: 9,925,138

« Back to Dashboard

Which drugs does patent 9,925,138 protect, and when does it expire?

Patent 9,925,138 protects TASCENSO ODT and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 9,925,138

Title:	Stable solid fingolimod dosage forms
Abstract:	The present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrates in a patient's oral cavity.
Inventor(s):	Fangyu Liu
Assignee:	Handa Neuroscience LLC
Application Number:	US15/084,226
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,925,138
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Device; Dosage form;

Drugs Protected by US Patent 9,925,138

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cycle	TASCENSO ODT	fingolimod lauryl sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	214962-001	Dec 23, 2021		RX	Yes	No	9,925,138		Y
Cycle	TASCENSO ODT	fingolimod lauryl sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	214962-002	Dec 9, 2022		RX	Yes	Yes	9,925,138		Y

International Family Members for US Patent 9,925,138

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016209466
Canada	2974375
China	107530301